Weiwei Zhou

Coordinated cellular programmes distinguish responses to neoadjuvant PD-L1 blockade and potentiate combinatorial immunotherapy in ESCC

Background Programmed death ligand 1 (PD-L1) blockade offers new therapeutic options for oesophageal squamous cell carcinoma (ESCC); however, the underlying mechanisms and associated biomarkers that determine treatment response remain unclear. Objective We delineate the mechanism...